3SBio Inc (83B) - Total Liabilities
Based on the latest financial reports, 3SBio Inc (83B) has total liabilities worth €5.81 Billion EUR (≈ $6.80 Billion USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore 83B net assets growth trend to track the company's year-over-year net asset growth rate.
3SBio Inc - Total Liabilities Trend (2016–2025)
This chart illustrates how 3SBio Inc's total liabilities have evolved over time, based on quarterly financial data. See 3SBio Inc (83B) FCF generation index to measure how efficiently the company converts operating cash flow to free cash.
3SBio Inc Competitors by Total Liabilities
The table below lists competitors of 3SBio Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Casella Waste Systems Inc
NASDAQ:CWST
|
USA | $1.70 Billion |
|
ESAB Corp
NYSE:ESAB
|
USA | $3.39 Billion |
|
Black Hills Corporation
NYSE:BKH
|
USA | $6.79 Billion |
|
Ultrapar Participacoes SA ADR
NYSE:UGP
|
USA | $6.54 Billion |
|
Garrett Motion Inc
NASDAQ:GTX
|
USA | $3.15 Billion |
|
Shenzhen Everwin Precision Tech
SHE:300115
|
China | CN¥16.84 Billion |
|
Coca-Cola Icecek AS
IS:CCOLA
|
Turkey | TL117.96 Billion |
|
Longfor Group Holdings Limited
F:RLF
|
Germany | €358.86 Billion |
Liability Composition Analysis (2016–2025)
This chart breaks down 3SBio Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see 3SBio Inc stock valuation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 5.13 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.21 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.16 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how 3SBio Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for 3SBio Inc (2016–2025)
The table below shows the annual total liabilities of 3SBio Inc from 2016 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €5.81 Billion ≈ $6.80 Billion |
-5.86% |
| 2024-12-31 | €6.18 Billion ≈ $7.22 Billion |
-13.15% |
| 2023-12-31 | €7.11 Billion ≈ $8.31 Billion |
+7.94% |
| 2022-12-31 | €6.59 Billion ≈ $7.70 Billion |
+44.64% |
| 2021-12-31 | €4.55 Billion ≈ $5.33 Billion |
-0.66% |
| 2020-12-31 | €4.58 Billion ≈ $5.36 Billion |
+3.03% |
| 2019-12-31 | €4.45 Billion ≈ $5.20 Billion |
-9.78% |
| 2018-12-31 | €4.93 Billion ≈ $5.77 Billion |
-19.45% |
| 2017-12-31 | €6.12 Billion ≈ $7.16 Billion |
+43.32% |
| 2016-12-31 | €4.27 Billion ≈ $4.99 Billion |
-- |
About 3SBio Inc
3SBio Inc., an investment holding company, engages in the development, production, marketing, and sale of biopharmaceutical products in the People's Republic of China, the United States, and internationally. The company offers TPIAO bio-pharmaceutical drug for the treatment of chemotherapy-induced thrombocytopenia, immune thrombocytopenia, pediatric ITP, and chronic liver disease-related thromboc… Read more